European Journal of Surgical Oncology
Volume 33, Issue 4 , Pages 438-443 , May 2007

Overexpression of Cripto and its prognostic significance in breast cancer: A study with long-term survival

  • Y.P. Gong

      Affiliations

    • Department of Breast Endocrine Surgery, Concord Repatriation General Hospital, Hospital Road, Concord NSW 2137, Australia
    • Permanent address: Department of Breast Surgery, Hubei Cancer Hospital, South Zhuodaoquan Road, Wuhan, Hubei 430079, People's Republic of China.
    • ,
  • P.M. Yarrow

      Affiliations

    • Department of Anatomical Pathology, Concord Repatriation General Hospital, Australia
    • ,
  • H.L. Carmalt

      Affiliations

    • Department of Breast Endocrine Surgery, Concord Repatriation General Hospital, Hospital Road, Concord NSW 2137, Australia
    • The Strathfield Breast Centre, 3 Everton Road, Strathfield NSW 2135, Australia
    • Corresponding Author InformationCorresponding author. The Strathfield Breast Centre, 3 Everton Road, Strathfield NSW 2135, Australia. Tel.: +61 2 97473789; fax: +61 2 97453714.
    • ,
  • S.Y. Kwun

      Affiliations

    • Department of Anatomical Pathology, Concord Repatriation General Hospital, Australia
    • ,
  • C.W. Kennedy

      Affiliations

    • The Strathfield Breast Centre, 3 Everton Road, Strathfield NSW 2135, Australia
    • ,
  • B.P.C. Lin

      Affiliations

    • Department of Anatomical Pathology, Concord Repatriation General Hospital, Australia
    • ,
  • P.X. Xing

      Affiliations

    • The Cancer Immunotherapy Laboratory, Burnet Institute, Studley Road, Heidelberg VIC 3084, Australia
    • ,
  • D.J. Gillett

      Affiliations

    • Department of Breast Endocrine Surgery, Concord Repatriation General Hospital, Hospital Road, Concord NSW 2137, Australia
    • The Strathfield Breast Centre, 3 Everton Road, Strathfield NSW 2135, Australia

,Accepted 9 October 2006.

References 

  1. Adamson Eileen D, Minchiotti Gabriella, Salomon David S. Cripto: a tumor growth factor and more. J Cell Physiol. 2002;190:267–278
  2. Qi CF, Liscia DS, Normanno N, et al. Expression of transforming growth factor alpha, amphiregulin and Cripto-1 in human breast carcinoma. Br J Cancer. 1994;69(5):903–910
  3. Saeki T, Stromberg K, Qi CF, et al. Differential immunohistochemical detection of amphiregulin and Cripto in human normal colon and colorectal tumors. Cancer Res. 1992;52(12):3467–3473
  4. Friess H, Yamanaka Y, Buchler M, Kobrin MS, Tahara E, Korc M. Cripto, a member of the epidermal growth factor family, is over-expressed in human pancreatic cancer and chronic pancreatitis. Int J Cancer. 1994;56(5):668–674
  5. Allgayer H, Heiss MM, Schildberg FW. Prognostic factors in gastric cancer. Br J Surg. 1997;84(12):1651–1664
  6. Fontanini G, De Laurentiis M, Vignati S, et al. Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I–IIIA non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic indicators of survival. Clin Cancer Res. 1998;4(1):241–249
  7. D'antonio A, Losito S, Pignata S, et al. Transforming growth factor alpha, amphiregulin and Cripto-1 are frequently expressed in advanced human ovarian carcinoma. Int J Oncol. 2002;21(5):941–948
  8. Kenney NJ, Adkins HB, Sanicola M. Nodal and Cripto-1: embryonic pattern formation genes involved in mammary gland development and tumorigenesis. J Mammary Gland Biol Neoplasia. 2004;9(2):133–144
  9. Bianco C, Strizzi L, Rehman A, et al. Nodal- and ALK4-independent signaling pathway activated by Cripto-1 through Glypican-1 and c-Src. Cancer Res. 1993;63:1192–1197
  10. Kannan S, De Santis M, Lohmeyer M, et al. Cripto enhances the tyrosine phosphorylation of Shc and activates mitogen-activated protein kinase (MAPK) in mammary epithelial cells. J Biol Chem. 1997;272:3330–3335
  11. Brandt R, Normanno N, Gullick WJ, et al. Identification and biological characterization of an epidermal growth factor-related protein: Cripto-1. J Biol Chem. 1994;269:17320–17328
  12. Ebert AD, Wechselberger C, Frank S, et al. Cripto-1 induces phosphatidylinositol 3′-kinase-dependent phosphorylation of AKT and glycogen synthase kinase 3beta in human cervical carcinoma cells. Cancer Res. 1999;59:4502–4505
  13. Datta SR, Brunet A, Greenberg ME. Cellular survival: a play in three Akts. Genes Dev. 1999;13:2905–2927
  14. Robinson MJ, Cobb MH. Mitogen-activated protein kinase pathways. Curr Opin Cell Biol. 1997;9:180–186
  15. Ebert AD, Wechselberger C, Nees M, et al. Cripto-1 induced increase in vimentin expression is associated with enhanced migration of human Caski cervical carcinoma cells. Exp Cell Res. 2000;257(1):223–229
  16. Thiery JP. Epithelial–mesenchymal transitions in tumor progression. Nat Rev Cancer. 2002;2:442–454
  17. Guarino M, Micheli P, Pallotti F, Giordano F. Pathological relevance of epithelial and mesenchymal phenotype plasticity. Pathol Res Pract. 1999;195:379–389
  18. Normanno N, De Luca A, Bianco C, et al. Cripto-1 overexpression leads to enhanced invasiveness and resistance to anoikis in human MCF-7 breast cancer cells. J Cell Physiol. 2004;198(1):31–39
  19. National Health & Medical Research Council . Clinical practice guidelines for the management of early breast cancer. 1st ed.. Canberra: The Australian Government Publishing Service; 1995;
  20. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19:403–410
  21. Salomon DS, Bianco C, Ebert AD, et al. The EGF-CFC family: novel epidermal growth factor-related proteins in development and cancer. Endocr Relat Cancer. 2004;7:199–226
  22. Adkins HB, Bianco C, Schiffer SG, et al. Antibody blockade of the Cripto CFC domain suppresses tumour cell growth in vivo. J Clin Invest. 2003;112:575–587
  23. Ertoy D, Ayhan A, Sarac E, et al. Clinicopathological implication of Cripto expression in early stage invasive cervical carcinomas. Eur J Cancer. 2000;36(8):1002–1007
  24. Ding J, Yang L, Yan YT, et al. Cripto is required for correct orientation of the anterior–posterior axis in the mouse embryo. Nature. 1998;395:702–707
  25. Morkel M, Huelsken J, Wakamiya M, et al. Beta-catenin regulates Cripto- and Wnt3-dependent gene expression programs in mouse axis and mesoderm formation. Development. 2003;130:6238–6294
  26. Niemeyer CC, Spencer-Dene B, Wu JX, Adamson ED. Preneoplastic mammary tumour markers: Cripto and Amphiregulin are overexpressed in hyperplastic stages of tumour progression in transgenic mice. Int J Cancer. 1999;81:588–591
  27. Xing PX, Hu XF, Pietersz GA, Hosick HL, McKenzie IF. Cripto: a novel target for antibody-based cancer immunotherapy. Cancer Res. 2004;64:4018–4023

PII: S0748-7983(06)00399-4

doi: 10.1016/j.ejso.2006.10.014

European Journal of Surgical Oncology
Volume 33, Issue 4 , Pages 438-443 , May 2007

Article Tools

* Image Usage & Resolution